The Body Covers: The 35th Annual Meeting of the Infectious Diseases Society of America
Effects of Switching from Saquinivir Hard Capsule (SQV-HC) to Saquinivir Soft Gel Capsules (SQV-SGC) or Indinavir (IDV)
Dr. Michael Para of Ohio State University reported on the results of an ACTG trial (#333) which evaluated the effects of switching from saquinavir hard capsules (SQV-HC)(1.8 grams/d) to saquinavir soft gel capsules (SQV-SGC) (7.2 grams/d) or indinavir (IDV) (2.4 grams/d), or continuing the SQV-HC. Otherwise, the patients were maintained on their stable nucleoside RTI combinations. The 72 participants had a mean plasma viral RNA level of 4.3 logs10 copies/ml, and a median CD4 count of 222 cells/mm3, and the median duration of SQV use was 112 weeks. The group that remained on SQV-HC had no significant change in their viral load over the first 6 months, but those who switched to SQV-SGC had a mean viral load decline of 0.4 log10 copies/ml, while those changed to IDV had a mean drop of 0.7 log10 copies/ml. CD4 cells tended to rise more in the group changed to SQV-SGC (mean of 37 cells/mm3) than the IDV group (22 cells/mm3). The data suggest that even after longterm SQV-HC exposure, there are some individuals who will have a virologic benefit from switching to the higher dose of the better absorbed SQV-SGC, or IDV.
This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.